Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. IL18BP - Wikipedia
IL18BP - Wikipedia
From Wikipedia, the free encyclopedia

Protein-coding gene in the species Homo sapiens
IL18BP
Identifiers
AliasesIL18BP, IL18BPa, interleukin 18 binding protein, FVH
External IDsOMIM: 604113; MGI: 1333800; HomoloGene: 7781; GeneCards: IL18BP; OMA:IL18BP - orthologs
Gene location (Human)
Chromosome 11 (human)
Chr.Chromosome 11 (human)[1]
Chromosome 11 (human)
Genomic location for IL18BP
Genomic location for IL18BP
Band11q13.4Start71,998,613 bp[1]
End72,005,715 bp[1]
Gene location (Mouse)
Chromosome 7 (mouse)
Chr.Chromosome 7 (mouse)[2]
Chromosome 7 (mouse)
Genomic location for IL18BP
Genomic location for IL18BP
Band7|7 E2Start101,664,092 bp[2]
End101,667,897 bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • spleen

  • upper lobe of left lung

  • granulocyte

  • mucosa of ileum

  • apex of heart

  • lymph node

  • right adrenal gland

  • left adrenal cortex

  • right lung

  • right adrenal cortex
Top expressed in
  • granulocyte

  • mesenteric lymph nodes

  • seminal vesicula

  • thymus

  • mucous cell of stomach

  • tail of embryo

  • liver

  • stroma of bone marrow

  • genital tubercle

  • fetal liver hematopoietic progenitor cell
More reference expression data
BioGPS
More reference expression data
Gene ontology
Molecular function
  • receptor antagonist activity
  • interleukin-18 binding
Cellular component
  • extracellular region
  • extracellular exosome
  • extracellular space
Biological process
  • T-helper 1 type immune response
  • cellular response to tumor necrosis factor
  • response to lipopolysaccharide
  • cellular response to hydrogen peroxide
  • extracellular negative regulation of signal transduction
  • interleukin-18-mediated signaling pathway
  • cellular response to cytokine stimulus
  • negative regulation of signaling receptor activity
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

10068

16068

Ensembl

ENSG00000137496

ENSMUSG00000070427

UniProt

O95998

Q9Z0M9

RefSeq (mRNA)
NM_001039659
NM_001039660
NM_001145055
NM_001145057
NM_005699

NM_173042
NM_173043
NM_173044

NM_010531
NM_001363982
NM_001382458

RefSeq (protein)
NP_001034748
NP_001034749
NP_001138527
NP_001138529
NP_005690

NP_766630
NP_766632
NP_766632.2

NP_034661
NP_001350911
NP_001369387

Location (UCSC)Chr 11: 72 – 72.01 MbChr 7: 101.66 – 101.67 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Interleukin-18-binding protein is a protein that in humans is encoded by the IL18BP gene.[5][6]

The protein encoded by this gene is an inhibitor of the proinflammatory cytokine IL18. This protein binds to IL18, prevents the binding of IL18 to its receptor, and thus inhibits IL18-induced IFN-gamma production. This protein is constitutively expressed and secreted in mononuclear cells. The expression of this protein can be enhanced by IFN-gamma. An elevated level of this protein is detected in the intestinal tissues of patients with Crohn's disease. Three transcript variants encoding the same protein have been found for this gene.[6]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000137496 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000070427 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M (Mar 1999). "Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response". Immunity. 10 (1): 127–36. doi:10.1016/S1074-7613(00)80013-8. PMID 10023777.
  6. ^ a b "Entrez Gene: IL18BP interleukin 18 binding protein".

Further reading

[edit]
  • Dinarello CA (2002). "Novel targets for interleukin 18 binding protein". Ann. Rheum. Dis. 60 (Suppl 3): iii18–24. doi:10.1136/ard.60.90003.iii18. PMC 1766679. PMID 11890646.
  • Loughney K, Martins TJ, Harris EA, et al. (1996). "Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases". J. Biol. Chem. 271 (2): 796–806. doi:10.1074/jbc.271.2.796. PMID 8557689.
  • Aizawa Y, Akita K, Taniai M, et al. (1999). "Cloning and expression of interleukin-18 binding protein". FEBS Lett. 445 (2–3): 338–42. Bibcode:1999FEBSL.445..338A. doi:10.1016/S0014-5793(99)00148-9. PMID 10094485. S2CID 21572907.
  • Xiang Y, Moss B (1999). "Identification of human and mouse homologs of the MC51L-53L-54L family of secreted glycoproteins encoded by the Molluscum contagiosum poxvirus". Virology. 257 (2): 297–302. doi:10.1006/viro.1999.9676. PMID 10329540.
  • Kim SH, Eisenstein M, Reznikov L, et al. (2000). "Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18". Proc. Natl. Acad. Sci. U.S.A. 97 (3): 1190–5. Bibcode:2000PNAS...97.1190K. doi:10.1073/pnas.97.3.1190. PMC 15564. PMID 10655506.
  • Dias Neto E, Correa RG, Verjovski-Almeida S, et al. (2000). "Shotgun sequencing of the human transcriptome with ORF expressed sequence tags". Proc. Natl. Acad. Sci. U.S.A. 97 (7): 3491–6. Bibcode:2000PNAS...97.3491D. doi:10.1073/pnas.97.7.3491. PMC 16267. PMID 10737800.
  • Michibata H, Yanaka N, Kanoh Y, et al. (2001). "Human Ca2+/calmodulin-dependent phosphodiesterase PDE1A: novel splice variants, their specific expression, genomic organization, and chromosomal localization". Biochim. Biophys. Acta. 1517 (2): 278–87. doi:10.1016/s0167-4781(00)00293-1. PMID 11342109.
  • Paulukat J, Bosmann M, Nold M, et al. (2001). "Expression and release of IL-18 binding protein in response to IFN-gamma". J. Immunol. 167 (12): 7038–43. doi:10.4049/jimmunol.167.12.7038. PMID 11739524.
  • Fidock M, Miller M, Lanfear J (2002). "Isolation and differential tissue distribution of two human cDNAs encoding PDE1 splice variants". Cell. Signal. 14 (1): 53–60. doi:10.1016/S0898-6568(01)00207-8. PMID 11747989.
  • Corbaz A, ten Hove T, Herren S, et al. (2002). "IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease". J. Immunol. 168 (7): 3608–16. doi:10.4049/jimmunol.168.7.3608. PMID 11907126.
  • Bufler P, Azam T, Gamboni-Robertson F, et al. (2002). "A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity". Proc. Natl. Acad. Sci. U.S.A. 99 (21): 13723–8. Bibcode:2002PNAS...9913723B. doi:10.1073/pnas.212519099. PMC 129755. PMID 12381835.
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. Bibcode:2002PNAS...9916899M. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
  • Hurgin V, Novick D, Rubinstein M (2003). "The promoter of IL-18 binding protein: Activation by an IFN-γ-induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein β". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16957–62. doi:10.1073/pnas.262663399. PMC 139251. PMID 12482935.
  • Plitz T, Saint-Mézard P, Satho M, et al. (2003). "IL-18 binding protein protects against contact hypersensitivity". J. Immunol. 171 (3): 1164–71. doi:10.4049/jimmunol.171.3.1164. PMID 12874202.
  • Fantuzzi G, Banda NK, Guthridge C, et al. (2004). "Generation and characterization of mice transgenic for human IL-18-binding protein isoform a". J. Leukoc. Biol. 74 (5): 889–96. doi:10.1189/jlb.0503230. PMID 12960225. S2CID 23024026.
  • Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
  • Kawashima M, Novick D, Rubinstein M, Miossec P (2004). "Regulation of interleukin-18 binding protein production by blood and synovial cells from patients with rheumatoid arthritis". Arthritis Rheum. 50 (6): 1800–5. doi:10.1002/art.20320. PMID 15188356.
  • Zhang Z, Henzel WJ (2005). "Signal peptide prediction based on analysis of experimentally verified cleavage sites". Protein Sci. 13 (10): 2819–24. doi:10.1110/ps.04682504. PMC 2286551. PMID 15340161.

External links

[edit]
  • IL18BP human gene location in the UCSC Genome Browser.
  • IL18BP human gene details in the UCSC Genome Browser.
  • v
  • t
  • e
Interleukin receptor modulators
IL-1
  • Agonists: Interleukin 1 (α, β)
  • Mobenakin
  • Pifonakin
  • Antagonists: AF-12198
  • Anakinra
  • IL-1RA
  • Isunakinra
  • Antibodies: Canakinumab
  • Gevokizumab
  • Lutikizumab
  • Decoy receptors: Rilonacept (IL-1 Trap)
IL-2
  • Agonists: Adargileukin alfa
  • Aldesleukin
  • Celmoleukin
  • Denileukin diftitox
  • Interleukin 2
  • Pegaldesleukin
  • Teceleukin
  • Tucotuzumab celmoleukin
  • Antibodies: Basiliximab
  • Daclizumab (dacliximab)
  • Inolimomab
IL-3
  • Agonists: Daniplestim
  • Interleukin 3
  • Leridistim
  • Milodistim
  • Muplestim
  • Promegapoietin
IL-4
  • Agonists: Binetrakin
  • Interleukin 4
  • Interleukin 13
  • Antagonists: Pitrakinra
  • Antibodies: Dupilumab
  • Pascolizumab
IL-5
  • Agonists: Interleukin 5
  • Antagonists: YM-90709
  • Antibodies: Benralizumab
  • Mepolizumab
  • Reslizumab
  • Antisense oligonucleotides: TPI ASM8
IL-6
  • Agonists: Atexakin alfa
  • Interleukin 6
  • Antibodies: ARGX-109
  • Clazakizumab
  • Elsilimomab
  • mAb 1339
  • Olokizumab
  • Sarilumab
  • Siltuximab
  • Sirukumab
  • Tocilizumab
  • Levilimab
IL-7
  • Agonists: Interleukin 7
IL-8
  • See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.
IL-9
  • Agonists: Interleukin 9
  • Antibodies: Enokizumab
IL-10
  • Agonists: Ilodecakin
  • Interleukin 10 (CSIF)
IL-11
  • Agonists: Interleukin 11 (AGIF)
  • Oprelvekin
IL-12
  • Agonists: Edodekin alfa
  • Interleukin 12
  • Antibodies: Briakinumab
  • Ustekinumab
IL-13
  • Agonists: Binetrakin
  • Cintredekin besudotox
  • Interleukin 4
  • Interleukin 13
  • Antibodies: Anrukinzumab
  • Lebrikizumab
  • Tralokinumab
IL-15
  • Agonists: ALT-803
  • Interleukin 15
IL-17
  • Agonists: Interleukin 17 (A, B, C, D, E (interleukin 25), F)
  • Antibodies: Brodalumab
  • Ixekizumab
  • Perakizumab
  • Remtolumab
  • Secukinumab
  • Vunakizumab
IL-18
  • Agonists: Iboctadekin
  • Interleukin 18
  • Interleukin 37
  • Tadekinig
  • Binding proteins: IL18BP
IL-20
  • Agonists: Interleukin 19
  • Interleukin 20
  • Interleukin 24
  • Antibodies: Fletikumab (against IL-20)
IL-21
  • Agonists: Denenicokin
  • Interleukin 21
  • Antibodies: NNC0114-0005
  • NNC0114-0006
IL-22
  • Agonists: Interleukin 22
  • Antibodies: Fezakinumab (against IL-22)
IL-23
  • Agonists: Interleukin 23 (SGRF)
  • Antibodies: Brazikumab
  • Briakinumab
  • Guselkumab
  • Risankizumab
  • Tildrakizumab
  • Ustekinumab
IL-27
  • Agonists: Interleukin 27 (interleukin 30)
IL-28
  • Agonists: Interferon λ4 (IFN-λ4)
  • Interleukin 28 (A (IFN-λ2), B (IFN-λ3))
  • Interleukin-29 (IFN-λ1)
IL-31
  • Agonists: Interleukin 31
IL1RL1
  • Agonists: Interleukin 33
IL1RL2
  • Agonists: Interleukin 36 (α, β, γ)
  • Interleukin 38
  • Antagonists: IL-36RA
Others
JAK
  • See here instead.
Others
  • Interleukin 14 (taxilin alpha, HMW-BCGF)
  • Interleukin 16 (signals through CD4)
  • Interleukin 24 (signals through IL-22Rα1/IL-20Rβ heterodimer)
  • Interleukin 26 (signals through IL-20Rα/IL-10Rβ heterodimer)
  • Interleukin 32
  • Interleukin 34 (signals through M-CSFR/CSF1R)
  • Interleukin 35
  • Unsorted: Efavaleukin alfa
  • Efineptakin alfa
Stub icon

This article on a gene on human chromosome 11 is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=IL18BP&oldid=1301323499"
Categories:
  • Genes on human chromosome 11
  • Human chromosome 11 gene stubs
Hidden categories:
  • Articles with short description
  • Short description matches Wikidata
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id